Source-grounded facts extracted from Marpai, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Marpai, Inc. incurred loan of $250,000 with Damien Lamendola at 12.0% per annum maturing May 10, 2026.
“On March 9, 2026, Marpai Inc. (the “Company”) issued a promissory note (the “Note”) in the principal amount of $250,000 to Damien Lamendola, the Company’s Chief Executive Officer (the “Holder”). The Note accrues interest at a rate of 12.0% per annum (or the maximum amount of interest allowed under the laws of the State of New York, whichever is less) until the Note is repaid in full.”
Marpai, Inc. incurred loan of $410,000 with Damien Lamendola at 12.0% per annum maturing April 11, 2026.
“On February 12, 2026, Marpai Inc. (the “Company”) issued a promissory note (the “Note”) in the principal amount of $410,000 to Damien Lamendola, the Company’s Chief Executive Officer (the “Holder”). The Note accrues interest at a rate of 12.0% per annum (or the maximum amount of interest allowed under the laws of the State of New York, whichever is less) until the Note is repaid in full. The Note may be prepaid by the Company, in whole or in part, together with all interest then accrued and any other sums then due and payable to the Holder, at any time, without premium or penalty. All payments of outstanding principal, interest and all other amounts due under the Note are payable by April 11, 2026 to the Holder, or its successors and assigns.”
Marpai, Inc. entered into Securities Purchase Agreement with certain investors valued at Expected gross proceeds of approximately $350,000; 350,000 shares of Class A common stock and warran (effective 2025-12-22).
“On December 22, 2025, Marpai Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain investors, pursuant to which the Company agreed to issue and sell an aggregate of: (i) 350,000 shares of its Class A common stock, par value $0.0001 per share (the “Common Stock”), and (ii) warrants (the “Common Warrants”) to purchase up to 700,000 shares of Common Stock in a private placement.”
Marpai, Inc. issued warrants to purchase up to 700,000 shares of Common Stock of warrant to certain investors.
“On December 22, 2025, Marpai Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain investors, pursuant to which the Company agreed to issue and sell an aggregate of: (i) 350,000 shares of its Class A common stock, par value $0.0001 per share (the “Common Stock”), and (ii) warrants (the “Common Warrants”) to purchase up to 700,000 shares of Common Stock in a private placement.”
Marpai, Inc. issued 350,000 shares of its Class A common stock of common stock to certain investors for purchase price for each share of Common Stock and accompanying Common Warrant is $1.00.
““Common Warrants”) to purchase up to 700,000 shares of Common Stock in a private placement. The purchase price for each share of Common Stock and accompanying Common Warrant is $1.00. The Common Warrants have an exercise price of $1.00 per share, can be exercised immediately following the closing of the private placement offering and will be exercisable for”
Marpai, Inc. issued up to 7,700,000 shares of Common Stock of warrant to certain investors, including the Company’s Chief Operating Officer and President, the chairman of the Company’s board of directors and certain directors of the Board for $1.00 per share.
“Warrants”) to purchase up to 7,700,000 shares of Common Stock in a private placement. The purchase price for each share of Common Stock and accompanying Common Warrant is $1.00. The Common Warrants have an exercise price of $1.00 per share, can be exercised immediately following the closing of the private placement offering and will be exercisable”
Marpai, Inc. issued 3,850,000 shares of its Class A common stock of common stock to certain investors, including the Company’s Chief Operating Officer and President, the chairman of the Company’s board of directors and certain directors of the Board for $1.00.
“Warrants”) to purchase up to 7,700,000 shares of Common Stock in a private placement. The purchase price for each share of Common Stock and accompanying Common Warrant is $1.00. The Common Warrants have an exercise price of $1.00 per share, can be exercised immediately following the closing of the private placement offering and will be exercisable”
Marpai, Inc.: Amendment to authorize 2,000,000 shares of blank-check preferred stock (effective 2025-10-17).
“the Company’s Amendment to the Second Amended and Restated Certificate of Incorporation (the “Amended Certificate of Incorporation”) was amended to authorize 2,000,000 shares of preferred stock, which shares shall be “blank-check preferred stock” in one or more series as solely determined by the Company’s board of directors (the “Board”)”
Marpai, Inc. issued an aggregate of 147,058 shares of its Class A common stock of common stock to HillCour Investment Fund, LLC for at a purchase price of $1.36 per share.
“the Company agreed to issue and sell an aggregate of 147,058 shares of its Class A common stock (the “Common Stock”) in a private placement, at a purchase price of $1.36 per share.”
Marpai, Inc. issued 1,038,519 shares of common stock to three investors, including HillCour Investment Fund, LLC for $1.0592 per share.
“of 1,038,519 shares of its Class A common stock (the “Common Stock”) (of which HillCour purchased 896,903 shares of Common Stock) in a private placement, at a purchase price of $1.0592 per share. The securities issued in the offering are exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”) pursuant to Section”
Dallas Scrip was appointed as Chief Operating Officer at Marpai, Inc..
“On May 13, 2025, the Board of Directors of Marpai, Inc. (the “Company”) appointed Dallas Scrip, age 42, as Chief Operating Officer of the Company, effective as of June 2, 2025.”
Mike Dendy resigned as Director at Marpai, Inc..
“On May 12, 2024, Mike Dendy notified the board of directors (the “Board”) of Marpai, Inc. (the “Company”) of his resignation from the Board, effective immediately.”
Marpai, Inc. reported the three months ended March 31, 2024 results: revenue $7.4 million, net income $4.3 million, EPS ($0.46).
“Net revenues were approximately $7.4 million for the three months ended March 31, 2024, down $2.3 million, or 24% lower year over year, compared to the three months ended March 31, 2023.”
Marpai, Inc. shareholders approved Approval of an amendment to the Company’s Certificate of Incorporation to include 2,000,000 shares of preferred stock, which shares shall be "blank-check preferred stock" in one or more series as solely determined by the Board, and to have the voting powers, preferences and relative participation, o at the 2024-05-06 meeting.
“Proposal No. 4 — Approval of an amendment to the Company’s Certificate of Incorporation to include 2,000,000 shares of preferred stock, which shares shall be "blank-check preferred stock" in one or more series as solely determined by the Board, and to have the voting powers, preferences and relative participation, optional and special rights and qualifications, limitations and restrictions thereof as solely determined by the Board.”
Marpai, Inc. shareholders approved Ratification of the appointment by the Audit Committee of the Board of UHY LLP, as the Company’s independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024. at the 2024-05-06 meeting.
“Proposal No. 3 — Ratification of the appointment by the Audit Committee of the Board of UHY LLP, as the Company’s independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024.”
Marpai, Inc. shareholders approved Approval of the Plan at the 2024-05-06 meeting.
“Proposal No. 2 — Approval of the Plan.”
Marpai, Inc. shareholders approved Election of Directors at the 2024-05-06 meeting.
“Proposal No. 1 — Election of Directors The stockholders elected the following individuals as directors of the Company to hold office until the next annual meeting of stockholders or until their successors shall have been duly elected and qualified.”
Marpai, Inc. incurred convertible notes of $11,830,000 with JGB Collateral LLC, as collateral agent at prime interest rate plus 5.75% per annum maturing April 15, 2027.
“the Company agreed to sell to the Purchasers Senior Secured Convertible Debentures (the “Debentures”) in an aggregate principal amount of $11,830,000”
Marpai, Inc. entered into Securities Purchase Agreement with the Purchasers valued at $11,830,000 (effective 2024-04-15).
“On April 15, 2024, Marpai, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with each of the purchasers that are parties thereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”) and JGB Collateral LLC, a Delaware limited liability company, as collateral agent for the Purchasers (the “Agent”).”
Marpai, Inc. reported the year ended December 31, 2023 results: revenue $37.2 million, net income Net loss was $28.8 million, EPS ($4.14).
“Net revenues were $37.2 million for the year ended December 31, 2023, an improvement of $12.8 million, or 52.6% higher year over year compared to the year ended December 31, 2022.”
Marpai, Inc. reported the three months ended December 31, 2023 results: revenue $8.7 million, net income Net loss was $5.0 million, EPS ($0.65).
“Net revenues were $8.7 million for the three months ended December 31, 2023, an improvement of $1.1 million, or 14% higher year over year, for the three months ended December 31, 2022.”
Marpai, Inc. entered into Securities Purchase Agreement with HillCour Investment Fund, LLC valued at $1.65 per share (effective 2024-03-07).
“On March 7, 2024, Marpai Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with HillCour Investment Fund, LLC, an entity controlled by the Company’s Chief Executive Officer, Damien Lamendola, pursuant to which the Company agreed to issue and sell 910,000 shares of its Class A common stock (the “Common Stock”) in a private placement, at a purchase price of $1.65 per share”
Marpai, Inc. reported the fourth quarter and fiscal year 2023 results: revenue approximately $8.7 million.
“expects to hold a webcast to discuss the results on March 27, 2024. Financial Highlights: • Net Revenues o For the fourth quarter of 2023, net revenues were approximately $8.7 million, an improvement of nearly $1.1 million or approximately 14% higher from the fourth quarter of 2022. o Full year 2023 net revenues were approximately $37.2 million, an improvement”
Marpai, Inc. reported the fourth quarter and fiscal year 2023 results: revenue approximately $8.7 million.
“expects to hold a webcast to discuss the results on March 27, 2024. Financial Highlights: • Net Revenues o For the fourth quarter of 2023, net revenues were approximately $8.7 million, an improvement of nearly $1.1 million or approximately 14% higher from the fourth quarter of 2022. o Full year 2023 net revenues were approximately $37.2 million, an improvement”
Marpai, Inc. entered into Agreement of Sale of Future Receipts with Libertas Funding LLC valued at $2,193,000 (effective 2024-02-05).
“On February 5, 2024, the Company entered into an Agreement of Sale of Future Receipts (the “Libertas Agreement”) with Libertas Funding LLC (“Libertas”) to sell future receipts totaling $2,193,000 for a purchase price of $1,700,000.”
Marpai, Inc. amended Amendment No. 1 to Purchase Agreement with AXA S.A. (effective 2024-02-07).
“On February 7, 2024, Marpai, Inc. (the “Company”) entered into Amendment No. 1 to Purchase Agreement (the “AXA Amendment”) with AXA S.A., a French société anonyme (“AXA”).”
Gonen Antebi resigned as Chief Operating Officer at Marpai, Inc..
“Gonen Antebi, the Company’s Chief Operating Officer, resigned from his position.”
John Powers was appointed as President and Chief Operating Officer at Marpai, Inc..
“appointed John Powers as President and Chief Operating Officer of the Company, effective as of January 2, 2024.”
Marpai, Inc. entered into Securities Purchase Agreement with certain Company insiders consisting of HillCour Investment Fund, LLC, Damien Lamendola, Yaron Eitan, and Robert Pons valued at $0.9201 per share (effective 2024-01-16).
“On January 16, 2024, Marpai Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain Company insiders consisting of HillCour Investment Fund, LLC, an entity controlled by the Company’s Chief Executive Officer, Damien Lamendola, the Company’s Chairman, Yaron Eitan, and the Company’s director, Robert Pons, pursuant to which the Company agreed to issue and sell 1,322,100 shares of its Class A common stock (the “Common Stock”) in a private placement, at a purchase price of $0.9201 per share”
Marpai, Inc. entered into Securities Purchase Agreement with HillCour Investment Fund, LLC valued at 150,000 shares of Class A common stock at $1.97 per share (effective 2023-12-14).
“On December 14, 2023, Marpai Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with HillCour Investment Fund, LLC, an entity controlled by the Company’s Chief Executive Officer, Damien Lamendola, pursuant to which the Company agreed to issue and sell 150,000 shares of its Class A common stock (the “Common Stock”) in a private placement, at a purchase price of $1.97 per share (or the consolidated closing bid price of the Company’s Common Stock on Nasdaq as of December 14, 2023).”
Steve Johnson was appointed as Secretary at Marpai, Inc..
“Steve Johnson, the Company’s Chief Financial Officer, has been appointed as the Company’s new Secretary, replacing Mr. Gonzalez.”
Edmundo Gonzalez resigned as Director and Secretary at Marpai, Inc..
“Edmundo Gonzalez, age 49, resigned as a member of the Board and as Secretary of the Company, each with immediate effect.”
Jenn Calabrese was appointed as Director at Marpai, Inc..
“On December 7, 2023, the Board of Directors (the “Board”) of Marpai, Inc. (the “Company”) appointed Robert Pons, age 67, and Jenn Calabrese, age 53, as new members of the Board.”
Robert Pons was appointed as Director at Marpai, Inc..
“On December 7, 2023, the Board of Directors (the “Board”) of Marpai, Inc. (the “Company”) appointed Robert Pons, age 67, and Jenn Calabrese, age 53, as new members of the Board.”
Yoram Bibring departed as Chief Financial Officer at Marpai, Inc..
“On December 5, 2023, the Company executed a Separation Agreement (the "Bibring Agreement") with Yoram Bibring, the Company’s former Chief Financial Officer.”
Edmundo Gonzalez departed as Chief Executive Officer at Marpai, Inc..
“On December 6, 2023, Marpai, Inc. (the "Company") executed a Separation Agreement (the "Gonzalez Agreement") with Edmundo Gonzalez, the Company’s former Chief Executive Officer.”
Marpai, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).
“November 28, 2023, the Company received a letter (the “Delisting Notice”) from Nasdaq stating that, as a result of the Company not regaining compliance with the MVLS Requirement, its securities would be delisted from the Nasdaq Capital Market, effective as of the opening of the market on December 7, 2023. The Delisting Notice provided that the Company may appeal the delisting determination to a Hearings Panel. The Company intends to immediately file an appeal, which would suspend the delisting until the Hearings Panel has made a final determination.”
Marpai, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).
“May 31, 2023, Marpai, Inc. (the “Company”) received a notification letter (the “Notice) from The Nasdaq Stock Market LLC(“Nasdaq”) notifying the Company that for the last 30 consecutive business dayspreceding the date of the Notice, the Company’s Market Value of Listed Securities (“MVLS”) has been below the minimum of $35,000,000 required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq provided the Company with 180 calendar days, or until November 27, 2023, to regain compliance wit”
Marpai, Inc. reported three and nine months ended September 30, 2023 results: revenue $8.7 million, net income nearly $7.3 million, EPS ($0.98) per share.
“Health, LLC (“Maestro Health”) since its acquisition on November 1, 2022. Third Quarter 2023 Highlights: • Total revenue for the three months ended September 30, 2023 was $8.7 million, representing an increase of $3.8 million, or nearly 77%, over the same period in 2022. The primary reason for this increase was due to the revenue from the acquisition of”
Mike Dendy was appointed as member of the Board at Marpai, Inc..
“On November 6, 2023, the Board appointed Mike Dendy, age 65, as a member of the Board.”
Vincent Kane resigned as member of the Board at Marpai, Inc..
“On November 6, 2023, Vincent Kane, age 49, resigned as a member of the Board, the Audit Committee and the Compensation Committee of the Board. Mr. Kane did not resign as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Yoram Bibring departed as Chief Financial Officer at Marpai, Inc..
“On November 6, 2023, the Board dismissed Yoram Bibring as the Company’s CFO.”
Steve Johnson was appointed as Chief Financial Officer at Marpai, Inc..
“Effective November 6, 2023, Steve Johnson, age 53, was appointed to serve as the Company’s Chief Financial Officer (the “CFO”).”
Edmundo Gonzalez departed as Chief Executive Officer at Marpai, Inc..
“On November 6, 2023, the Board dismissed Edmundo Gonzalez as the CEO of the Company.”
Damien Lamendola was appointed as Chief Executive Officer at Marpai, Inc..
“On November 6, 2023, the Board of Directors (the “Board”) of Marpai, Inc. (the “Company”) appointed Damien Lamendola, age 66, to serve as the Chief Executive Officer (the “CEO”) of the Company.”
Marpai, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“October 6, 2023, Marpai, Inc. (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company did not satisfy the requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”) to maintain a minimum bid price of $1.00 per share. The Company became deficient with Rule 5550(a)(2) as of October 6, 2023 as the closing bid price of its Class A common stock was less than $1.00 per share for 30 consecutive business days prior to the date o”
Lutz Finger was terminated as President of Product and Development at Marpai, Inc..
“On August 16, 2023, Marpai, Inc. (the “Company”) executed a Separation Agreement (the “Agreement”) with Mr. Lutz Finger, the Company’s President of Product and Development, pursuant to which Mr. Finger’s position was terminated effective as of August 15, 2023.”
Marpai, Inc. reported Q2 2023 results: revenue $9.5 million to $9.8 million. Guidance reaffirmed.
“Marpai Confirms Revenue Guidance for Q2 2023 of $9.5 Million to $9.8 Million Company cites expected improvements in EBITDA NEW YORK—( BUSINESS WIRE )— Marpai, Inc .—June 29, 2023—("Marpai" or the "Company") (Nasdaq: MRAI), an AI-powered Third-Party Administrator (TPA) transforming self-funded employer health plans, confirmed its revenue guidance for Q2 2023 as between $9.5 million to $9.8 million.”
Marpai, Inc.: Reverse stock split at 1-for-4 ratio (effective 2023-06-29).
“Effective as of June 29, 2023, Marpai, Inc. (the “Company”) effected a reverse stock split of its outstanding shares of Class A common stock (the “common stock”) at a ratio of one-for-four (the “Reverse Split”).”
Marpai, Inc. shareholders approved Authorization of the Company's Board of the Directors to Amend the Certificate of Incorporation to Effect a Reverse Stock Split of All Outstanding Shares of Class A Common Stock at the 2023-06-26 meeting.
“Proposal No. 1 - Authorization of the Company’s Board of the Directors to Amend the Certificate of Incorporation to Effect a Reverse Stock Split of All Outstanding Shares of Class A Common Stock The Company’s stockholders voted to authorize the Company’s Board of Directors to amend the Company’s Certificate of Incorporation, as amended, to effect a reverse split of the Company’s issued and outstanding shares of Class A common stock, $0.0001 par value per share, at a ratio of not less than one-for-two (1:2) and not greater than one-for-five (1:5), to be implemented no later than December 31, 2023, as determined by the Board in its sole discretion: For Against Abstain Broker Non-Votes 17,374,153 729,672 1,810 N/A”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.